HOME > LATEST
LATEST
-
REGULATORY MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
-
BUSINESS Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
-
ORGANIZATION Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
-
REGULATORY Cabinet OKs Subsidy to Boost Antibiotic API Stockpiles, Allocates 7.1 Billion Yen from Reserve
January 21, 2026
-
BUSINESS Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
-
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
-
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
-
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
-
REGULATORY Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
-
REGULATORY Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
-
ORGANIZATION JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
January 20, 2026
-
BUSINESS Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
-
BUSINESS Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
-
BUSINESS Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
-
REGULATORY Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
-
REGULATORY Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
-
BUSINESS Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
-
REGULATORY Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026
-
BUSINESS 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
-
BUSINESS Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
